Feb 6 (Reuters) - Eli Lilly and Co LLY.N:
LILLY EXEC SAYS UPTAKE OF SINGLE-USE ZEPBOUND VIALS INCREASED IN Q4 THROUGH DIRECT TO CONSUMER WEBSITE SALES - CONF CALL
LILLY EXEC SAYS U.S. ZEPBOUND PERFORMANCE IS GOING VERY WELL
LILLY EXEC SAYS IN Q4 ZEPBOUND BECAME THE MARKET LEADER IN THE ANTI-OBESITY MARKET AS MEASURED BY NEW PRESCRIPTIONS
LILLY EXEC SAYS U.S. PRESCRIPTIONS OF ALZHEIMER'S DRUG KISUNLA STEADILY INCREASING SINCE LAUNCH
LILLY EXEC SAYS CO PLANS TO START SEVERAL TRIALS ASSESSING INCRETINS IN AREAS SUCH AS BRAIN HEALTH, SUBSTANCE USE DISORDERS, PAIN, OTHERS
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。